CLAIMS

1. Use of a composition comprising at least torasemide and baclofen, or salts, or sustained release formulations thereof, for the manufacture of a medicament for promoting nerve or neuron regeneration in a subject suffering from a nerve injury selected from neuropraxia, axonotmesis or neurotmesis, or from a neuropathy caused by direct physical nerve injury or of genetic origin.

2. The use of claim 1, wherein said medicament further comprises a composition comprising at least one compound selected from sulfisoxazole, methimazole, prilocaine, dyphylline, quinacrine, carbenoxolone, acamprosate, aminocaproic acid, cabergoline, diethylcarbamazine, cinacalcet, cinnarizine, eplerenone, fenoldopam, leflunomide, levosimendan, sulodexide, terbinafine, zonisamide, etomidate, phenformin, trimetazidine, mexiletine, ifenprodil, moxifloxacin, or bromocriptine, or salts, or sustained release formulations thereof.

3. The use of claim 2, wherein said medicament comprises at least one of the following combinations of compounds:

   - baclofen and trimetazidine and torasemide,
   - baclofen and cinacalcet and torasemide,
   - baclofen and acamprosate and torasemide,
   - baclofen and acamprosate and torasemide and diethylcarbamazine, or
   - baclofen and acamprosate and torasemide and ifenprodil.

4. The use according to any one of the preceding claims, wherein said medicament further comprises a pharmaceutically acceptable carrier or excipient.

5. The use according to any one of the preceding claims, wherein the compounds are formulated to be administered together, separately or sequentially.

6. The use according to any one of the preceding claims, wherein the compounds are formulated to be administered repeatedly to the subject.

7. The use according to claim 1, wherein the subject is suffering from a Charcot-Marie-Tooth disease.

8. The use according to any one of the preceding claims, wherein the dose of torasemide is less than 4 mg.

9. The use according to any one of the preceding claims, wherein the dose of baclofen is less than 150 mg, preferably less than 50 mg.

10. The use according to any one of the preceding claims, wherein said medicament is to be administered orally.

11. Use of torasemide or a salt, or a sustained release formulations thereof, for the manufacture of a medicament for promoting nerve or neuron regeneration in a subject suffering from a nerve injury selected from neuropraxia, axonotmesis or neurotmesis, or from a neuropathy caused by direct physical nerve injury or of genetic origin, wherein said medicament is formulated to be administered in combination with baclofen or a salt, or a sustained release formulation thereof.